Is a complete SABS research report available?

No complete published report is available for SAB Biotherapeutics, Inc. (SABS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · USD

$3.56

+0.08 (+2.3%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first SABS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	272.2M
Net income (ttm)	-9.4M
EPS (ttm)	-$2.05
Shares out	76.5M
Volume	208,625
Beta	0.53
Price target	$11.2	+214.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -9.4M
EPS (ttm): -$2.05
Market cap: 272.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All SABS indicators

Market & fundamental data

Available fields

189

Groups with data

Currency

USD

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001833214
Company name	SAB Biotherapeutics, Inc.
Country	United States
Country code	US
Cusip	78397T202
Employees	86
Employees Change	23%
Employees Change Percent	36.51
Enterprise value	$170.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US78397T2024
Last refreshed	2026-07-31
Market cap	$272.2M
Market cap category	Micro-Cap
Price	$3.56
Price currency	USD
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2836
Symbol	SABS
Website	https://www.sab.bio

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.47%
FCF yield	-19.59%
P/B ratio	1.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-39.1M
Net Income	$-9.4M
Net Income Growth Years	2%
Profit Per Employee	$-109,428
Profitable Years	1
ROA	-25.38
Roa5y	-28.98
ROCE	-24.38
ROE	-0.32
Roe5y	-52.1
ROIC	-27.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	57.22%
Cagr3y	-24.92%
Cagr5y	-48.58%
EPS Growth Quarters	3
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$248.5M
Cash	$107.4M
Current Assets	$112.8M
Current Liabilities	$9.9M
Debt	$6.2M
Debt Equity	$0.03
Equity	$227.2M
Interest Coverage	-248.8
Liabilities	$21.2M
Long Term Assets	$135.7M
Long Term Liabilities	$11.4M
Net Cash	$101.2M
Net Cash By Market Cap	$37.29
Net Cash Growth	1,568.24%
Net Debt Equity	$-0.45
Tangible Book Value	$227.2M
Tangible Book Value Per Share	$3
WACC	7.07

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	11.45
Net Working Capital	$-3.5M
Quick ratio	11.06
Working Capital	$102.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-227.56%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	57.17%
200-day SMA	3.72
3Y total return	-57.69%
50-day SMA	3.66
50-day SMA vs 200-day SMA	50under200
5Y total return	-96.4%
All Time High	129
All Time High Change	-97.24%
All Time High Date	2021-10-22
All Time Low	1
All Time Low Change	256%
All Time Low Date	2025-04-04
ATR	0.19
Beta	0.53
Beta1y	0.82
Beta2y	0.96
Ch YTD	-4.81
High	3.59
High52	5.15
High52 Date	2026-03-12
High52ch	-30.87%
Low	3.46
Low52	1.85
Low52 Date	2025-09-30
Low52ch	92.43%
Ma50ch	-2.76%
Premarket Change Percent	-2.3
Premarket Price	$3.4
Premarket Volume	1,146
Price vs 200-day SMA	-4.28%
RSI	46.12
RSI Monthly	37.92
RSI Weekly	49.06
Sharpe ratio	0.92x
Sortino ratio	1.58
Total Return	-227.56%
Tr YTD	-4.81
Tr1m	-8.72%
Tr1w	-0.56%
Tr3m	2.3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	2
Analyst Price Target Top	$14.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.28
Operating Income	$-58.2M
Price target	$11.18
Price Target Change	$214
Price Target Change Top	$307

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,199,356%
Float Percent	53.88%
Net Borrowing	-283,887
Shares Insiders	0.77%
Shares Institutions	46.49%
Shares Out	76,464,094
Shares Qo Q	11.59%
Shares Yo Y	227.56%
Short Float	10.62%
Short Ratio	3.68
Short Shares	5.72

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-63.2M
Adjusted OCF	-61,306,631
Average Volume	516,710.2x
Bv Per Share	3
CAPEX	$-1.9M
Ch1m	-8.72
Ch1w	-0.56
Ch1y	57.17
Ch3m	2.3
Ch3y	-57.69
Ch5y	-96.4
Ch6m	-19.46
Change	2.3%
Change From Open	2.01
Close	3.48
Days Gap	0.29
Depreciation Amortization	3,055,955
Dollar Volume	742,705
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$-58.2M
EBITDA	$-55.1M
EPS	$-2.05
F Score	1
FCF	$-53.2M
FCF EV Yield	-31.23x
FCF Per Share	$-0.7
Financing CF	258,394,558
Fiscal Year End	December
Founded	2,014
Investing CF	-192,024,909
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Date	2024-01-05
Last Split Type	Reverse
Last10k Filing Date	2026-03-09
Ma150	3.82
Ma150ch	-6.9%
Ma20	3.66
Ma20ch	-2.73%
Net CF	14,879,357
Next Earnings Date	2026-08-06
Open	3.49
Optionable	Yes
Position In Range	76.19
Post Close	3.56
Postmarket Change Percent	-0.28
Postmarket Price	$3.55
Ppne	20,173,207
Pre Close	3.48
Price Date	2026-07-30
Ptbv Ratio	1.19
Relative Volume	0.4x
Share Based Comp	10,057,607
Tr6m	-19.46%
Us State	Florida
Volume	208,625

SAB Biotherapeutics, Inc. (SABS)

Coverage state: Market snapshot only — no published research

Generate the first SABS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · SABS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SABS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on SABS

Frequently asked questions